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Abstract 
Background: Magnesium sulfate (MgSO4) is the most effective seizure prophylaxis in the management of severe pre-
eclampsia, and its use is progressively spreading in our environment. It was introduced at the pioneer teaching hospital 
of southeastern Nigeria in 2007. A study on the outcome of its use is therefore necessary.
Objectives: The objective was to determine the effect of introducing MgSO4 on the maternal and perinatal outcomes 
of severe pre-eclampsia in Enugu, South eastern Nigeria. 
Materials and Methods: A retrospective study of all cases of severe pre-eclampsia managed at the University of Nigeria 
Teaching Hospital Enugu (UNTH), Nigeria, from 1 January 2005 to 31 December 2008 - 2 years before, and 2 years 
after the introduction of MgSO4 – was performed. 
Result: The prevalence of severe preeclampsia within the study period was 3.3%. The mean age of study participants 
was 24.5 ± 2.9 years. Thirty women received MgSO4 while 47 women received diazepam. Eclampsia occurred only in 
a member of the diazepam group but there were no maternal deaths. Babies from the diazepam group were more likely 
to have low 1 minute Apgar scores but the association was not significant [OR = 3.08 (95% CI 0.78, 13.33)]. Longer 
hospital stay was significantly lower among women who received MgSO4 [OR = 0.32 (95% CI 0.11, 0.93)]. Perinatal 
mortality did not differ between the groups. 
Conclusion: MgSO4 is effective in the management of severe pre-eclamptics at the UNTH, Enugu. Therefore, its 
accessibility and wider use should be promoted.
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Pre-eclampsia is a pregnancy-associated syndrome occurring 
in the second half of pregnancy and characterized by 
hypertension and significant proteinuria.[1] It complicates 
about 5-10% of pregnancies.[2] Together with its major 
complication – eclampsia, it is a major cause of maternal 
and perinatal morbidity and mortality both in Nigeria and 
internationally.[3-7] Its widespread and effective management 
would therefore contribute significantly toward achieving 
the Millennium Development Goals (MDGs) 4, 5. The 
aetiology of the disorder is unknown; nevertheless, it has 
been linked to abnormal placentation,[2] which may explain 
the fact that the definitive cure of the disorder cannot be 
achieved without delivery of the placenta. Pre-eclampsia 
is classified into mild and severe types based majorly on 
the woman’s blood pressure and proteinuria.[1] The severe 
form is characterized by severe hypertension and significant 
proteinuria among other features.[8] 
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The management of severe pre-eclampsia involves the use of 
drugs in the control of blood pressure and seizure prophylaxis 
-- the latter employs drugs such as diazepam, phenytoin, and 
magnesium sulfate (MgSO4).[9] Emerging evidence suggests 
that MgSO4 is superior to other anticonvulsants in the 
management of severe pre-eclampsia/ eclampsia.[10] In line 
with this, there has been increasing use of MgSO4 in health 
institutions in Nigeria.[11,12] From the year 2007, the use of 
intramuscular MgSO4 regimen replaced diazepam in the 
protocol for the management of pre-eclampsia/eclampsia 
at the University of Nigeria Teaching Hospital (UNTH), 
Enugu, Nigeria. 
This study aimed to review the maternal and perinatal 
outcome of severe pre-eclampsia since the introduction 
of MgSO4 at the UNTH Enugu and compare the findings 
with those of preceding years. 
Materials and Methods 
The study was a retrospective study of 2 cohorts of women 
managed for severe pre-eclampsia at the University of 
Nigeria Teaching Hospital Ituku--Ozalla, Enugu from 
2005 to 2008. The first (MgSO4) cohort was made of 
those managed from January 2007 (to December 2008) 
when intramuscular (Pritchard) regime of MgSO4,[13] was 
introduced as seizure prophylaxis. The second (diazepam) 
cohort consisted of those managed from January 2005 
to December 2006 and received diazepam as seizure 
prophylaxis. Exclusion criteria included history of seizure 
prior to admission, and chronic hypertension. 
The case notes of the patients were retrieved from the Records 
department of the hospital. Patients’ biodata and relevant 
outcome variables were sought for and recorded in a data 
sheet prepared for the study. Maternal outcome variables 
were the occurrence of seizure (eclampsia) after initiation of 
seizure prophylaxis, duration of hospital stay, and maternal 
deaths. Perinatal outcome variables were Apgar score at 1 
and 5 minutes, perinatal deaths, and early neonatal deaths. 
Data analysis was by both descriptive and inferential 
statistics at 95% confidence level using SPSS software for 
Windows version 13.0. Frequency tables were generated for 
relevant variables. Proportions were compared with the 
Pearson chi--square test. Relationships were expressed using 
odd ratio and confidence intervals. 
The diagnosis of severe pre-eclampsia was made in a woman 
with pre-eclampsia in line with standard protocols which 
include a diastolic blood pressure equal to or greater than 
(≥) 110 mmHg or systolic blood pressure ≥160 mm Hg or 
urine protein is ≥5 g/24 hours.[1,9] 
A low Apgar score at 1 or 5 minutes was defined as a score 
of 6 or less. 
Prolonged hospital stay was defined as a hospital stay of 
more than 7 days following cesarean delivery or more than 
2 days following vaginal delivery. 
The UNTH, Enugu is a teaching hospital which offers 
both primary and specialist care to pregnant women in 
Enugu state of Nigeria and its environment. The relevant 
characteristics of the study center and Enugu state had been 
described in an earlier report.[14]
Results
During the 48-month study period, there were 77 cases 
of severe pre-eclampsia and 2337 deliveries which gave a 
prevalence rate of 3.3%. The mean age of the participants 
was 24.5 ± 2.9 years (range = 15--45 years). The modal age 
group was 20-29 years and it consisted of 39 (50.6%) women. 
Fifty nine (76.6%) women registered and received antenatal 
care at the study center while the remaining were referred 
cases. Most participants (49.4%) were primigravidae, and 
the commonest range of gestational age at presentation was 
34--36 weeks. Details of the socio--demographic and other 
characteristics are shown in Table 1. 
The diazepam cohort consisted of 47 women while the 
MgSO4 cohort had 30 women. None of the patients in the 
MgSO4 group had seizures after the commencement of the 
drug, while one woman from the diazepam group had an 
episode of tonic clonic seizures. There were no maternal 
deaths in either of the groups. 





Age group (years) < 20 2 2.6
20-29 39 50.6
30-39 27 35.1
> 40 9 11.7
Parity group Para 0 38 49.3
Para 1-4 31 40.3
Para 5 and above 8 10.4









Route of delivery Vaginal 33 41.8
Cesarean 46 58.2
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The superior efficacy of MgSO4 in the management of 
preeclampsia/eclampsia has been confirmed.[19] Pritchard 
regimen is prescribed at the study center in preference to the 
intravenous regimen because of the ease of administration 
and inaccessibility of infusion pumps.[20] The use of MgSO4 
as seizure prophylaxis in cases of severe pre-eclampsia 
reduces the risk of developing eclampsia by more than 
half.[10] This was evident in this study where eclampsia was 
observed only in the diazepam group. Furthermore, it may 
not be surprising that no maternal death was recorded in 
this study irrespective of the type of seizure prophylaxis used 
because the prompt commencement of seizure prophylaxis 
in severe pre-eclamptic is associated with lower incidence 
of maternal death.[10] 
In this study, a newborn with a low 1-minute Apgar score 
was three times more likely to belong to a woman who 
received diazepam as seizure prophylaxis, when compared 
to the MgSO4 group. The risk, however, reduced to 1.4 in 5 
minutes probably due to the effect of resuscitation. Though 
these associations were not statistically significant [Table 1], 
they are still noteworthy because they suggest that diazepam 
crosses the placenta at a substantial dose to affect the fetus. 
Therefore, there is a need to ensure the availability of basic 
skills and equipment for newborn resuscitation in centers 
where diazepam is still used for the management of severe 
pre-eclampsia. The reason for the observed significant 
increase in hospital stay among the diazepam group was 
not clear and calls for further studies. 
Severe preeclampsia is also injurious to the fetus and this 
was reflected in the study by the high proportion (45.5%) 
of low birth weight babies and high perinatal case fatality of 
32.5%. Nevertheless, the likelihood of perinatal death did 
not vary between the MgSO4 and diazepam groups. 
The study is limited by its retrospective nature and 
dependence on patients’ records. It is likely that substantial 
measurement bias might have occurred especially with 
Apgar scoring but it was probably nondirectional and 
therefore, would not have increased the study estimates. It 
was also assumed that patients’ management in either group 
was strictly in line with the hospital’s protocol but that might 
Fourteen neonates from the diazepam group had low Apgar 
score at 1 minute as against 4 neonates from the MgSO4 
group. Babies from the diazepam group were more likely 
to have low 1-minute Apgar scores but the association 
was not significant [OR = 3.08 (95% CI 0.78, 13.33)]. 
On the other hand, only four and two neonates from the 
diazepam and MgSO4 groups had low Apgar score at 5 
minutes respectively. Details of the relationships between 
the MgSO4 and diazepam groups with respect to Apgar 
scores are shown in Table 2. 
Furthermore, out of the 77 women studied, 36 (46.8%) had 
a prolonged hospital stay: 9 (11.7%) women in the MgSO4 
group and 27 (35.1%) in the diazepam group. The observed 
difference was statistically significant [OR = 0.32 (95% CI 
0.11, 0.93)]. 
On the other hand, the 77 pre-eclamptic women delivered 
79 babies (2 were twin deliveries); 25 babies died within 
the perinatal period giving a perinatal case fatality rate of 
32.5%. There were 10 perinatal deaths (5 stillbirths and 5 
early neonatal deaths) in the MgSO4 group which did not 
vary significantly with the 15 perinatal deaths (9 stillbirths 
and 6 early neonatal deaths) in the diazepam group [OR 
= 1.05 (95% CI 0.36, 3.07)]. A similar relationship was 
observed when proportions of early neonatal deaths between 
the MgSO4 and diazepam groups were compared [OR = 
1.31 (95% CI 0.30, 5.73)].
Discussion
Pre-eclampsia is a common complication of pregnancy. 
The severe type occurs in about 25% of all cases.[15] The 
prevalence of severe pre-eclampsia of 3.3% observed in this 
study was higher than 0.3% reported from Nepal, South 
Asia.[16] More than half (76.6%) of all cases identified 
in this study received antenatal care at the study center 
which underscores the importance of antenatal care in the 
detection of pre-eclampsia so as to prevent its complications 
and improve feto-maternal outcome. The participants’ 
mean age, parity, and gestational age distribution of the cases 
were similar to those from related reports.[12,17,18] 
Table 2: Relationship between diazepam and MgSO4 groups versus Apgar scores
Anticonvulsant Low Apgar scores at 1 minute P value OR (CI 95%)
Yes (%) No (%)
Diazepam MgSO4 14 (35.9) 25 (64.1) 0.070 3.08 (0.78, 13.33)
4 (15.4) 22 (84.6) - -
Total* 18 (27.7) 47 (72.3)
Low Apgar score 5 minute
Diazepam MgSO4 4 (10.3) 35 (89.7) 0.726 1.37 (0.19, 11.85)
2 (7.7) 24 (92.3) - -
Total* 6 (9.2) 59 (90.8)
*The 14 stillbirths excluded.
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not have been the case in our environment where payment 
for health care is essentially out of pocket. Furthermore, a 
larger number of participants could have produced more 
precise study results. Despite this limitation, the study has 
initiated the process of filling the existing gap on severe 
preeclampsia and the use of MgSO4 in our environment. 
In conclusion, this study has shown reduced perinatal 
morbidity (low Apgar score) and maternal morbidity 
(eclampsia and longer hospital stay) among severe 
preeclamptic women who received MgSO4 when compared 
to those who received diazepam. These findings support 
the superiority of MgSO4 in the management of severe 
preeclampsia. Because pre-eclampsia/eclampsia is a 
leading cause of maternal mortality in Nigeria, improved 
accessibility and wider use of MgSO4 are very important in 
our struggle to achieve the targets of MDG 5. 
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